ZIVO Bioscience, a leading biotech/agtech company focused on developing therapeutic, medicinal, and nutritional products from proprietary algal cultures, has announced positive results from a recent 42-day study of its coccidiosis treatment for broiler chickens. Conducted in collaboration with a major global animal health company and mimicking real-world poultry production conditions, the study further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating treatment for coccidiosis.
The study, funded by the collaborating animal health company, assessed the overall health and productivity of chickens infected with the coccidiosis-causing parasite Eimeria. It compared the effects of ZIVO’s product alone and in combination with an ionophore-based treatment or a coccidiosis vaccine, against birds treated with only the ionophore or vaccine. Uninfected/untreated and infected/untreated birds served as negative and positive disease controls, respectively.
Results showed that broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with either the ionophore or vaccine demonstrated statistically significant improvements in growth performance (measured by feed conversion ratio, FCR) and clinical signs of disease (assessed by intestinal lesion scores) compared to those receiving only the ionophore or vaccine. Notably, the FCR for groups treated with ZIVO’s product alongside either the ionophore or vaccine matched that of the healthy, uninfected control group over the 42-day period.
John Payne, Chairman and CEO of ZIVO Bioscience, expressed his satisfaction with the study’s findings: “We are thrilled to report that our product has proven effective in supporting poultry health and productivity in the presence of coccidiosis. These results underscore our product’s versatility, showing it can enhance existing treatment options and serve as a standalone treatment. Maintaining feed conversion ratios comparable to uninfected birds highlights the significant value our product offers to the poultry industry.”
Payne added, “Coccidiosis remains one of the most challenging and costly diseases in poultry production. The potential to improve outcomes using our product in conjunction with current treatments could represent a significant advancement in disease management. We are eager to continue discussions with global animal health companies as we prepare for commercial market entry.”
